timothy sykes logo
CELZ Stock Surges As New Diabetes Patent Fuels Momentum Thumbnail
G Google News

CELZ Stock Surges As New Diabetes Patent Fuels Momentum

JACK KELLOGG•UPDATED AUG. 7, 2026, 8:32 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Creative Medical Technology Holdings Inc. stocks have been trading up by 22.61 percent amid highly positive biotechnology breakthrough sentiment.

Key Takeaways

  • Creative Medical Technology Holdings received a USPTO Notice of Allowance for a new U.S. patent covering exosome-based immunotherapy for Type 1 diabetes, bolstering its MyeloCelz platform.
  • The new CELZ patent strengthens the company’s diabetes-focused intellectual property and may support future partnerships or licensing, but brings no fresh clinical data or regulatory approvals.
  • Shares of CELZ jumped over 30% in premarket trading after a prior 1.9% gain, with the move driven largely by price momentum rather than a clear new catalyst.
  • The USPTO notice covers exosomes from stem cell–programmed myeloid cells to suppress diabetes, reinforcing Creative Medical Technology’s exosome-based therapeutic approach.

Candlestick Chart

Live Update At 08:32:13 EDT: On Friday, August 07, 2026 Creative Medical Technology Holdings Inc. stock [NASDAQ: CELZ] is trending up by 22.61%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CELZ is acting like a classic low-float biotech momentum play, but the financials tell a different, more cautious story. Creative Medical Technology Holdings reported quarterly revenue of just $6,000, with revenue trending down sharply over three and five years. For traders, that screams “early-stage story stock,” not a revenue machine.

The company posted a net loss of about $1.41M for the recent quarter, translating to a diluted EPS of roughly -$0.38 on around 3.7M diluted shares. Profitability metrics are deep in the red, with returns on assets and equity heavily negative. CELZ is burning cash, with operating cash flow near -$1.32M for the period.

On the balance sheet, though, CELZ is not falling apart. The company shows roughly $5.72M in cash and restricted cash at period end, a very strong current ratio near 19.7, and effectively no debt. That gives CELZ some runway to keep funding its diabetes programs.

More Breaking News

Valuation looks stretched on traditional metrics. With revenue so small, the price‑to‑sales ratio sits in the thousands, which is normal for a speculative biotech but a warning label for any trader who only chases the chart.

Why Traders Are Watching CELZ Now

CELZ grabbed trader attention after a clean one-two punch: fresh patent news and a sharp premarket spike. Creative Medical Technology Holdings received a USPTO Notice of Allowance for a new patent covering exosome-based immunotherapy for Type 1 diabetes, tied to its MyeloCelz platform. This protection complements existing CELZ-101, CELZ-201, and CELZ-001 programs, tightening the company’s IP grip around exosome-based diabetes strategies.

For traders, patents like this matter because they shape the story. CELZ now has stronger positioning if larger pharma players go shopping for diabetes innovation or exosome platforms. A Notice of Allowance signals the patent will be granted, locking in proprietary rights around using exosomes from stem cell–programmed myeloid cells to suppress diabetes. That is real, tangible progress on the IP front.

But the key is what the patent is not. It is not a new Phase 2 readout. It is not an FDA green light. CELZ has no fresh clinical data or approvals tied to this news. So fundamentally, the long-term optionality improves, while the near-term risk profile barely changes.

The market, however, rarely waits for nuance. CELZ exploded more than 30% in premarket trading, extending a modest 1.9% gain the prior session. The tape shows a classic momentum chase: once CELZ started to move, more traders piled in, chasing the range from sub-$0.70 closes into highs above $1.70 intraday. The intraday 5‑minute chart shows a series of higher lows through the premarket, with CELZ grinding from the mid‑$1.20s up into the $1.40s before the regular session — a clear sign of aggressive dip-buying and scalping.

Short-term, CELZ is a volatility engine. Longer-term, it is still a high‑risk clinical story with strengthening IP but unproven commercial value.

Conclusion

CELZ sits at the crossroads of hype and hard numbers. On one side, Creative Medical Technology just secured a powerful USPTO Notice of Allowance around exosome-based Type 1 diabetes therapy, tightening the moat around its MyeloCelz platform and programs like CELZ-101, CELZ-201, and CELZ-001. The patent on exosomes from stem cell–programmed myeloid cells to suppress diabetes gives CELZ a more defensible story and raises the odds of future partnership talks or licensing interest.

On the other side, the financials still scream early-stage risk. Revenue is minimal, losses are heavy, and the entire CELZ bull case rests on successful execution in the clinic and the boardroom. The recent 30%+ premarket surge shows traders are willing to pay up for that story when a catalyst — even an IP-focused one — hits the wire.

For active traders, the job now is simple but not easy: respect the volatility, trade the chart, and stay honest about the fundamentals. CELZ has cash, a clean balance sheet, and a stronger patent wall, but it remains a speculative biotech. As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” That mindset is crucial when navigating fast moves like this, where adapting your trading approach and learning from every trade can matter more than nailing any single setup.

As Tim Sykes loves to remind his students, “Patterns repeat, but you still need a plan for every trade.” CELZ is giving traders a pattern right now — a patent-fueled momentum spike. The edge goes to those who study the moves, cut losses fast, and treat this as education and research, not a lottery ticket.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”